ABEMACICLIB

ABEMACICLIB : ATP competitive inhibitor of CDK4, CDK6

Structure

Information

  • CDK4
  • CDK6
  • competitive ATP inhibitor
  • up to 2 uM

In Vitro Validations

Uniprot ID: P11802
Target Class: Kinase
Target SubClass: CMGC
Potency: IC50
Potency Value: 2 nM
Potency Assay: radiometric-filter binding assay
PDB ID for probe-target interaction (3D structure): 7SJ3 5L2S 7O7K 7O7J
Target aliases:
Cyclin-dependent kinase 4, CDK4, CDK4_HUMAN, PSK-J ...

DOI Reference: 10.1007/s10637-014-0120-7

Uniprot ID: P11802
Target Class: Kinase
Target SubClass: CMGC
Potency: Ki
Potency Value: 0.6 nM
Potency Assay: radiometric-filter binding assay
PDB ID for probe-target interaction (3D structure): 7SJ3 5L2S 7O7K 7O7J
Target aliases:
Cyclin-dependent kinase 4, CDK4, CDK4_HUMAN, PSK-J ...

DOI Reference: 10.1007/s10637-014-0120-7

In Cell Validations

In Vivo Data

Off-Target Selectivity Assesments

Potency assay (off target): Selectivity was evaluated in a panel of 100 protein kinases (Millipore/UBI). Profiled against 456 kinases (KINOMEscan, DiscoverRx) for single point binding at 200 nM and 2 μM concentrations: at 2 uM shows a binding profile significantly concentrated in the CGMC family of kinases that comprises cyclin-dependent kinases and MAPK kinases.
I have extra information to add

SERP ratings and comments


SERP Ratings

In Cell Rating
In Model Organisms

SERP Comments:

This probe is of high quality and has good selectivity for its target. However, at concentrations below the recommended there are issues with in-family selectivity which may make making conclusions more complex given the linked phenotype. A non-active probe control would also have been useful for here. Overall, this is a nicely designed probe that can be used to interrogate the target.

(last updated: 22 Jun 2023 )

SERP Ratings

In Cell Rating
In Model Organisms

SERP Comments:

Abemaciclib is a potent inhibitor of many CDKs as well as many CMGC family member such as DYRK1A and HIP kinases. It would be not be possible to assign a function in cells to CDK4/6 based on Abemaciclib alone. Orthogonal approaches or probes and dose-response data may be required.

(last updated: 17 Jul 2023 )